Best Peptides for Liver Health

A quick vocabulary note, because the trials use precise terms. MASLD (metabolic dysfunction-associated steatotic liver disease, formerly NAFLD) is the broad condition — fat stored in the liver. MASH (metabolic dysfunction-associated steatohepatitis, formerly NASH) is the advanced, inflammatory subset where fat is accompanied by cell injury and often fibrosis (scarring). MASH is what the strongest peptide trials targeted, because it is the stage most likely to progress toward cirrhosis.

The Rankings

1. Semaglutide — the deepest Phase 3 liver dataset

Best for: readers tracking the most mature clinical evidence, particularly where fibrosis — not just liver fat — is the endpoint of interest.

Semaglutide is a GLP-1 receptor agonist and the only peptide on this list with a completed, powered Phase 3 trial reporting a significant fibrosis-improvement result in MASH. Its mechanism in the liver is described in published research as extending beyond weight loss: GLP-1 receptor activation is reported to reduce hepatic production of new fat, lower systemic inflammation, and improve insulin sensitivity — the metabolic driver behind fat accumulation in the liver.

The ESSENCE trial (Phase 3) randomized adults with biopsy-confirmed non-cirrhotic MASH and stage F2-F3 fibrosis to semaglutide 2.4 mg weekly or placebo. At 72 weeks, the trial reported MASH resolution without worsening of fibrosis in 62.9% of the semaglutide group versus 34.3% on placebo, and fibrosis improvement without worsening of MASH in 37.0% versus 22.5% (both statistically significant). The fibrosis result is what separates semaglutide from the rest of the class — it is the only powered Phase 3 fibrosis endpoint reported to date.

Community reports on semaglutide used in a metabolic context cluster around three themes: gradual appetite reduction over the first weeks of dose escalation, gastrointestinal side effects that peak during titration and ease afterward, and liver-enzyme (ALT, AST) improvements that self-reported timelines and real-world data commonly describe appearing over roughly 24-36 weeks. The most consistent community caveat is the same one trials document across the GLP-1 class — the metabolic benefit depends on continued dosing.

Deep dive: Best Semaglutide Vendors | Semaglutide Dosing Guide | Semaglutide Results Timeline

2. Tirzepatide — the dual-incretin with strong MASH resolution

Best for: readers interested in the dual-incretin mechanism and MASH resolution numbers, who note the fibrosis data is not yet from a powered Phase 3 endpoint.

Tirzepatide activates two incretin receptors — GLP-1 and GIP. Published research describes the dual mechanism as reducing liver lipid uptake through the CD36 and OBP2A transport pathways, a liver-specific effect trial authors suggest may operate partly independent of total weight loss.

The SYNERGY-NASH trial (Phase 2) tested three tirzepatide doses in adults with biopsy-confirmed MASH and stage F2-F3 fibrosis. At 52 weeks, the peer-reviewed primary endpoint reported MASH resolution without worsening of fibrosis in 51.8% (5 mg), 62.8% (10 mg), and 73.3% (15 mg) of patients versus 13.2% on placebo (efficacy estimand; the more conservative treatment-policy analysis reported 43.6% / 55.5% / 62.4%). Fibrosis improvement of at least one stage was reported as a secondary endpoint at roughly half of patients on the highest dose — a promising but not yet Phase 3-powered signal. A Phase 3 outcomes trial launched in late 2025.

Community reports on tirzepatide in a metabolic context describe appetite reduction comparable to or stronger than single-incretin agents, a gastrointestinal side-effect profile that eases after titration, and — in self-reported liver-marker tracking — ALT and AST trends similar to those described for semaglutide. Trial data, not community reports, remains the basis for any liver-specific claim; the community signal here is metabolic, not histological.

Deep dive: Best Tirzepatide Vendors | Tirzepatide Dosing Guide | Semaglutide vs Tirzepatide

3. Retatrutide — the largest reported liver-fat reduction

Best for: readers tracking the cutting edge of hepatic-fat pharmacology who accept that the strongest liver-fat numbers come from the earliest-stage evidence.

Retatrutide adds glucagon receptor activation to the GLP-1 + GIP framework. Published research describes the glucagon arm as directly increasing hepatic fat oxidation — a mechanism trial authors highlight as particularly relevant to liver fat, distinct from appetite-driven weight loss alone.

A dedicated Phase 2a trial in patients with MASLD reported relative liver-fat reductions of 81.4% (8 mg) and 82.4% (12 mg) at 24 weeks versus roughly no change on placebo, with approximately 93% of the highest-dose group reaching normal liver fat (under 5%). The larger Phase 2 obesity trial reported a consistent signal in its prespecified hepatic-steatosis subgroup, where mean liver-fat reduction reached the low-to-mid 80% range at higher doses by 48 weeks. Those are the largest liver-fat reductions reported for any peptide — but the data is Phase 2a, measured liver fat rather than fibrosis staging, and Phase 3 liver trials are still pending.

Community reports on retatrutide are thinner than for the established compounds, reflecting its investigational status. Available reports cluster around strong appetite reduction and a broader early side-effect profile attributed to the glucagon component, including more frequent reports of mild nausea and occasional heart-rate elevation. Community sources commonly describe variable product quality at lower-tier vendors, a recurring theme for compounds still in trials.

Deep dive: Best Retatrutide Vendors | Retatrutide Dosing Guide | Retatrutide Benefits

For readers whose interest is broader fat loss rather than liver-specific data, these three compounds also anchor the best peptides for fat loss ranking — the weight-loss trial evidence for each is deeper still. For the news context on the regulatory side, see the coverage of GLP-1s approved for fatty liver disease.

How Metabolic Peptides Act on the Liver

The reason the GLP-1-class compounds have liver data — and the antioxidant and repair peptides do not — comes down to mechanism. Published research describes several liver-specific pathways that operate alongside, and partly independent of, the weight loss these compounds produce.

Reduced de novo lipogenesis. GLP-1 receptor activation is described in published research as decreasing the liver's own production of new fat from carbohydrate. Because the liver's fat burden in MASLD is driven substantially by this internal manufacturing rather than dietary fat alone, published research describes dialing it down as addressing the condition at its source.

Lower hepatic lipid uptake. Trial authors attribute part of tirzepatide's effect to reduced expression of the CD36 and OBP2A transport proteins, which shuttle circulating fatty acids into liver cells. Fewer transporters means less fat delivered to the hepatocyte — a dual-incretin-specific mechanism the SYNERGY-NASH investigators highlighted to explain a dose-response beyond what weight loss alone predicts.

Increased fat oxidation. Retatrutide's glucagon-receptor arm is described in published research as directly raising hepatic fat oxidation — the liver burning its stored fat rather than accumulating it. This is the mechanistic basis trial authors offered for the exceptionally steep liver-fat reductions reported in the Phase 2a MASLD study.

Restored insulin sensitivity and lower inflammation. Hepatic insulin resistance is described across the trials as the metabolic engine behind fat accumulation and its progression to inflammation. Both semaglutide and tirzepatide trials reported improved insulin signaling and reduced systemic inflammatory markers, which trial authors describe as blunting the cascade that pushes simple steatosis toward the cell injury and fibrosis that define MASH.

By contrast, the preliminary-tier peptides rest on mechanisms that are either liver-relevant only in acute-injury animal models (BPC-157, TB-500) or antioxidant and metabolic in a general sense that has not translated to measured liver-fat reduction in controlled human trials (glutathione, NAD+). The mechanism gap is exactly why the evidence gap exists.

The Preliminary Tier: Peptides Without Human Liver-Disease Evidence

The compounds below appear constantly in community "liver support" discussions. None has human trial data establishing it as a treatment for fatty liver, MASH, or fibrosis. They are grouped separately and graded honestly — the point is to describe where the evidence actually sits, so preliminary signals are not mistaken for the clinical data above.

BPC-157 — rodent liver-protection data only

BPC-157 is a synthetic peptide studied in animal models for tissue repair. Its liver evidence is genuinely old and genuinely limited to rodents: a 1993 study reported that BPC-157 reduced liver lesions in rats across three injury models — restraint stress, bile-duct and hepatic-artery ligation, and carbon tetrachloride (CCl4) exposure. That is a hepatoprotective signal in acute chemical and surgical injury models, not fatty liver disease, and it has not been followed by human liver trials in the three decades since.

Community reports on BPC-157 focus overwhelmingly on gut and connective-tissue recovery rather than liver outcomes. Where liver "support" is described, it is extrapolation from the rodent injury data, not from any human liver-disease evidence. Described accurately, BPC-157's liver profile is preliminary and animal-only.

Deep dive: BPC-157 Benefits | BPC-157 Clinical Trials

TB-500 — systemic-repair peptide with no direct liver data

TB-500 (a synthetic fragment related to thymosin beta-4) is studied for systemic tissue repair and anti-inflammatory activity, largely in animal models of wound and cardiac injury. There is no human trial data evaluating it for fatty liver disease, and the "liver" association in community sources is an inference from its general anti-fibrotic and angiogenic activity in non-liver rodent work rather than a liver-specific finding.

Community reports pair TB-500 with BPC-157 for recovery use cases; liver benefit is not a documented outcome in either trial data or well-characterized community reporting. On the evidence, TB-500 belongs in this tier as an unproven extrapolation for liver purposes.

Deep dive: TB-500 Benefits | BPC-157 vs TB-500

Glutathione — one small open-label pilot in NAFLD

Glutathione is the body's principal intracellular antioxidant, and its "detox" framing is where most liver-support marketing lives. The human liver evidence is a single small pilot: an open-label, single-arm study reported that oral glutathione 300 mg/day for four months (following a three-month lifestyle run-in) lowered ALT, triglycerides, non-esterified fatty acids, and ferritin in 34 NAFLD patients. Because there was no placebo group and the design was single-arm, the result is difficult to attribute to glutathione itself rather than the concurrent lifestyle changes.

Community reports commonly describe glutathione for general antioxidant and skin purposes; liver-marker improvement is sometimes cited but rests on that one weak pilot. Described honestly, glutathione has a hypothesis-generating signal in NAFLD, not established efficacy.

Deep dive: Glutathione Benefits | Glutathione Dosing Guide

NAD+ — the metabolic story that did not move liver fat

NAD+ and its precursors are discussed for mitochondrial and metabolic health, and the liver is metabolically central — so the connection is plausible on paper. The strongest human test to date works against the hype: a double-blind, placebo-controlled trial of a nicotinamide riboside plus pterostilbene combination in 111 NAFLD adults reported no significant change in the primary endpoint of hepatic fat fraction versus placebo. Only secondary markers (ALT, GGT) shifted at the lower dose. That is effectively a negative result for the outcome that matters most in fatty liver — liver-fat reduction.

Community reports on NAD+ cluster around energy and general wellness rather than measured liver outcomes. Described accurately, the NAD+ liver story is indirect and, on the best available human evidence, unsupported for reducing liver fat.

Deep dive: NAD+ Benefits | NAD+ Dosing Guide

How Different Audiences Choose

Trial-evidence strength and community usage map onto a few clear reader profiles. Here is how the compounds above tend to break down.

Readers whose primary concern is documented fibrosis improvement have the narrowest field — only semaglutide has reported a statistically significant fibrosis-improvement endpoint in a powered Phase 3 trial (ESSENCE, 37.0% versus 22.5% at 72 weeks).

Readers focused on MASH resolution rates most often look at semaglutide and tirzepatide, the two compounds with biopsy-confirmed resolution data (62.9% and up to 73.3% respectively versus 13-34% on placebo).

Readers tracking the largest liver-fat reduction numbers commonly follow retatrutide, whose Phase 2a MASLD data reported the steepest liver-fat drops (up to 82.4% relative reduction at 24 weeks) — while noting the evidence is earlier-stage than the MASH resolution trials.

Readers drawn to antioxidant or "detox" framing encounter glutathione and NAD+ most often; the honest evidence picture is a single weak pilot for glutathione and a negative primary endpoint for the strongest NAD+-precursor trial.

Readers interested in tissue-repair peptides encounter BPC-157 and TB-500 in recovery communities; their liver association is rodent-only or extrapolated, not clinical.

For readers whose broader goal is metabolic weight loss (the driver behind most fatty liver), the best peptides for fat loss ranking covers the same top three in more depth, plus survodutide — a GLP-1/glucagon dual agonist whose Phase 2 program specifically reported liver-fat reduction in a MASLD population.

What Trial Data Describe as Signals of Effect

For the compounds with actual liver trials, three signals appear consistently in published research, in this order.

Weeks 12-24: Liver fat first. Imaging-based liver-fat measurement (MRI-PDFF) is where the GLP-1-class trials reported the earliest movement. ESSENCE and SYNERGY-NASH described hepatic-steatosis reductions detectable within the first 12 weeks, and the retatrutide MASLD trial measured its headline liver-fat reductions at 24 weeks. Fat is the fastest-moving liver signal in the trial data.

Weeks 24-36: Liver enzymes. ALT, AST, and GGT are the standard blood markers trial protocols tracked, and real-world reports commonly describe normalization over roughly 24-36 weeks on GLP-1 therapy — often before weight loss has plateaued. Trial monitoring schedules for glucagon-containing agents (retatrutide) paid particular attention to liver enzymes given the glucagon component's hepatic activity.

Weeks 52-72: Histology and fibrosis. Biopsy-confirmed MASH resolution was measured at 52 weeks in SYNERGY-NASH and 72 weeks in ESSENCE. Fibrosis is the slowest endpoint to move — trials describe it as harder to shift than fat or enzymes, which is why only semaglutide's 72-week Phase 3 fibrosis result reached significance. The headline numbers throughout this article reflect 52-72 weeks of continuous dosing, not short-term change.

Interpreting liver-peptide data without this timeline is what leads to overstatement. A liver-fat number at 24 weeks is not the same claim as a fibrosis-improvement number at 72 weeks, and the trials are careful to keep them separate.

Related Reading

• GLP-1s Now FDA-Approved for Fatty Liver Disease — the regulatory and market context behind the MASH approvals
• Best Semaglutide Vendors — buyer's guide for the deepest-data liver peptide
• Best Tirzepatide Vendors — buyer's guide for the dual-incretin option
• Semaglutide vs Tirzepatide — head-to-head across metabolic and liver endpoints
• Retatrutide Dosing Guide — protocol detail for the triple agonist
• Best Peptides for Fat Loss — the same top three, ranked for weight loss
• Best Peptides for Longevity — where NAD+ and glutathione actually have a stronger case

References